secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122814
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done
--------------------------------------------------------------------------------

- Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
- Completed $345M public equity offering to fund atacicept launch and regulatory submission.
- Phase 3 ORIGIN 3 trial enrollment complete; topline data expected in Q2 2025.
- Positive 96-week eGFR stabilization data from Phase 2 ORIGIN trial at ASN Kidney Week 2024.
- Expanded atacicept development with PIONEER trial in broader IgAN and other kidney diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024122814/0000950170-24-122814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024122814/vera-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer